Biodexa Pharmaceticals (BDRX)

Sep 23, 2026

Biodexa Pharmaceuticals PLC's CEO, Stephen Stamp, discussed the company's lead program, eRapa, for Familial Adenomatous Polyposis (FAP). eRapa is an oral drug candidate aiming to reduce or eliminate the need for surgery in FAP patients. A Phase 3 trial is over 50% enrolled, with an interim futility analysis expected in Q1 2027, supported by Orphan Drug designations and $20 million in grant funding.

Sep 15, 2026

Biodexa Pharmaceuticals (BDRX) stock has surged by 16.18% following positive developments in its Phase 3 Serenta trial for eRapa, targeting Familial Adenomatous Polyposis (FAP). The trial has reached the halfway enrollment mark with 87 of 168 patients, supported by a $20M CPRIT grant and Orphan Drug Designation. This progress de-risks the timeline and positions eRapa for potential market exclusivity, making BDRX a significant catalyst-driven trading opportunity despite its developmental-stage financial status.

Sep 15, 2026

Biodexa Pharmaceuticals plc (BDRX) stock has risen by 12.48% due to favorable clinical trial progress for its eRapa drug in the Phase 3 Serenta trial for Familial Adenomatous Polyposis (FAP). The company has reached the halfway point in patient enrollment, and the trial is supported by a $20M grant and Orphan Drug Designation. Despite minimal revenue and heavy losses typical for a clinical-stage biotech, BDRX's valuation is primarily driven by news from this potentially game-changing late-stage asset, making it a speculative but attractive play for active traders.

Sep 14, 2026

Biodexa Pharmaceuticals (NASDAQ: BDRX) has filed a prospectus for the resale of up to 170,150 ordinary shares, represented by 3,403 American Depositary Shares (ADSs), by selling shareholders. This transaction is structured as a shareholder resale rather than an issuer offering, with the securities trading on the Nasdaq Capital Market under the ticker BDRX. The prospectus supplement for this resale is dated September 11, 2026.